Grandfield & Dodd’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.17M | Sell |
16,462
-167
| -1% | -$22.2K | 0.12% | 81 |
|
|
2025
Q4 | $2.36M | Buy |
16,629
+3
| +0% | +$435 | 0.13% | 78 |
|
|
2025
Q3 | $2.33M | Buy |
16,626
+194
| +1% | +$26.3K | 0.13% | 80 |
|
|
2025
Q2 | $2.07M | Sell |
16,432
-138
| -0.8% | -$15.8K | 0.12% | 83 |
|
|
2025
Q1 | $1.83M | Buy |
16,570
+459
| +3% | +$58.1K | 0.11% | 89 |
|
|
2024
Q4 | $2.2M | Buy |
16,111
+290
| +2% | +$35.9K | 0.14% | 78 |
|
|
2024
Q3 | $1.82M | Buy |
15,821
+280
| +2% | +$38.4K | 0.11% | 90 |
|
|
2024
Q2 | $2.14M | Sell |
15,541
-53
| -0.3% | -$7.27K | 0.14% | 79 |
|
|
2024
Q1 | $2.15M | Buy |
15,594
+203
| +1% | +$27.7K | 0.14% | 78 |
|
|
2023
Q4 | $2.03M | Buy |
15,391
+196
| +1% | +$22.6K | 0.14% | 75 |
|
|
2023
Q3 | $1.71M | Sell |
15,195
-60
| -0.4% | -$6.32K | 0.13% | 80 |
|
|
2023
Q2 | $1.44M | Buy |
15,255
+77
| +0.5% | +$7.52K | 0.1% | 89 |
|
|
2023
Q1 | $1.54M | Buy |
15,178
+274
| +2% | +$28.5K | 0.11% | 85 |
|
|
2022
Q4 | $1.78M | Buy |
14,904
+625
| +4% | +$73.2K | 0.13% | 79 |
|
|
2022
Q3 | $1.52M | Buy |
14,279
+352
| +3% | +$35.7K | 0.12% | 81 |
|
|
2022
Q2 | $1.36M | Buy |
13,927
+130
| +0.9% | +$12K | 0.11% | 87 |
|
|
2022
Q1 | $1.29M | Buy |
13,797
+566
| +4% | +$48K | 0.09% | 94 |
|
|
2021
Q4 | $1.13M | Buy |
13,231
+1,324
| +11% | +$122K | 0.07% | 96 |
|
|
2021
Q3 | $1.14M | Buy |
11,907
+164
| +1% | +$15.5K | 0.08% | 91 |
|
|
2021
Q2 | $1.14M | Buy |
11,743
+190
| +2% | +$18.2K | 0.08% | 94 |
|
|
2021
Q1 | $1.12M | Buy |
11,553
+174
| +2% | +$18.2K | 0.08% | 92 |
|
|
2020
Q4 | $1.09M | Buy |
11,379
+262
| +2% | +$25.3K | 0.09% | 95 |
|
|
2020
Q3 | $1.07M | Buy |
11,117
+81
| +0.7% | +$9.37K | 0.1% | 92 |
|
|
2020
Q2 | $1.35M | Buy |
11,036
+600
| +6% | +$66.3K | 0.13% | 80 |
|
|
2020
Q1 | $903K | Buy |
10,436
+430
| +4% | +$42.1K | 0.11% | 89 |
|
|
2019
Q4 | $1.08M | Buy |
10,006
+540
| +6% | +$56.5K | 0.1% | 93 |
|
|
2019
Q3 | $853K | Buy |
9,466
+855
| +10% | +$79.9K | 0.08% | 98 |
|
|
2019
Q2 | $727K | Buy |
8,611
+730
| +9% | +$59.9K | 0.07% | 108 |
|
|
2019
Q1 | $694K | Buy |
7,881
+61
| +0.8% | +$5.1K | 0.07% | 111 |
|
|
2018
Q4 | $558K | Buy |
7,820
+65
| +0.8% | +$6.23K | 0.07% | 114 |
|
|
2018
Q3 | $953K | Buy |
7,755
+70
| +0.9% | +$7.94K | 0.1% | 100 |
|
|
2018
Q2 | $755K | Buy |
7,685
+40
| +0.5% | +$3.58K | 0.08% | 105 |
|
|
2018
Q1 | $634K | Sell |
7,645
-270
| -3% | -$22.8K | 0.07% | 112 |
|
|
2017
Q4 | $614K | Buy |
7,915
+305
| +4% | +$20.8K | 0.07% | 117 |
|
|
2017
Q3 | $466K | Buy |
7,610
+1,480
| +24% | +$78.1K | 0.05% | 135 |
|
|
2017
Q2 | $282K | Buy |
6,130
+810
| +15% | +$39.3K | 0.03% | 162 |
|
|
2017
Q1 | $230K | Buy |
+5,320
| New | +$228K | 0.03% | 173 |
|
Other funds holding NBIX
VPM
VCM
Grandfield & Dodd's NBIX Position: Q1 2026 in Review
Grandfield & Dodd reduced its Neurocrine Biosciences (NBIX) stake by 1% in Q1 2026, selling an estimated $22.2K and leaving 16,462 shares worth $2.17M. The position accounts for 0.12% of the portfolio, ranked #81.
Grandfield & Dodd first reported a position in NBIX in Q1 2017 and has held it in 37 quarters since. The position peaked at $2.36M in Q4 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Grandfield & Dodd held 16,462 shares of Neurocrine Biosciences worth $2.17M as of Q1 2026.
- Grandfield & Dodd sold 167 Neurocrine Biosciences shares in Q1 2026, an estimated $22.2K.
- Neurocrine Biosciences made up 0.12% of Grandfield & Dodd's portfolio in Q1 2026, its #81 holding.
- Grandfield & Dodd first reported a position in Neurocrine Biosciences in Q1 2017 and has held it in 37 quarters since.
- Grandfield & Dodd's Neurocrine Biosciences position peaked at $2.36M in Q4 2025.
- 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Grandfield & Dodd's 13F filing for Q1 2026, filed 7 May 2026.